Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Development of a peptide ELISA for discrimination between serological responses to equine herpesvirus type 1 and 4 (2013)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Lang, Annemarie (WE 5)
    de Vries, Maren
    Feineis, Silke (WE 5)
    Müller, Elisabeth
    Osterrieder, Nikolaus (WE 5)
    Damiani, Armando M (WE 5)
    Quelle
    Journal of Virological Methods; 193(2) — S. 667–673
    ISSN: 0166-0934
    Sprache
    Englisch
    Verweise
    DOI: 10.1016/j.jviromet.2013.07.044
    Pubmed: 23928223
    Kontakt
    Institut für Virologie

    Robert-von-Ostertag-Str. 7-13
    Gebäude 35
    14163 Berlin
    +49 30 838 51833
    viro@zedat.fu-berlin.de

    Abstract / Zusammenfassung

    A peptide-based enzyme-linked immunosorbent assay (ELISA) for discrimination between serological responses to equine herpesvirus type 1 (EHV-1) and 4 (EHV-4) was developed. Three and four peptides for EHV-1 and EHV-4, respectively, were designed and studied initially in the ELISA using sera from foals infected experimentally. The most promising peptide pair, derived from EHV-1 glycoprotein E and EHV-4 glycoprotein G, was evaluated further using acute and convalescent sera from horses infected experimentally and naturally as well as a panel of horse field sera. Ten pre- and post-vaccination serum pairs were similarly tested in the type-specific ELISA. The peptide ELISA was able to identify horses which had been infected with EHV-1 or EHV-4 as derived from the results using acute and convalescent sera collected from natural outbreaks. When applied to a set of field samples, the assay proved robust with respect to determining the EHV-1 and EHV-4 antibody status. Also, the peptide ELISA was able to detect type-specific seroconversion for EHV-1 in vaccinated animals. With further validation, the EHV-1/EHV-4 peptide ELISA described in this study could serve as a reliable and cost-effective alternative to current methods for serological EHV-1 and EHV-4 diagnosis.